In Brief: NSI Papnet
This article was originally published in The Gray Sheet
NSI Papnet: Neuromedical Systems, Inc. enters agreement with MagnaCare/MagnaHealth under which procedures conducted with NSI's Papnet automated Pap smear rescreening system will be covered through the physician provider network. MagnaCare covers approximately 3 mil. people, one quarter of whom will receive Papnet testing, NSI estimates. Charging $30-$40 per test, NSI anticipates generating monthly sales of $30,000 as a result of the pact...
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.